achieving-efficient-fragment-screening-at-xchem-facility-at-diamond

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

In fragment-based drug discovery, hundreds or often thousands of compounds smaller than ~300 Da are tested against the protein of interest to identify ...

University of Oxford

Oxford University

COVID-19, caused by SARS-CoV-2, lacks effective therapeutics. Additionally, no antiviral drugs or vaccines were developed against the closely related coronavirus, SARS-CoV-1 or MERS-CoV, despite previous zoonotic outbreaks. To identify starting points for such therapeutics, we performed a large-scale screen of electrophile and non-covalent fragments through a combined mass spectrometry and X-ray approach against the SARS-CoV-2 main protease, one of two cysteine viral proteases essential for viral replication. Our crystallographic screen identified 71 hits that span the entire active site, as well as 3 hits at the dimer interface. These structures reveal routes to rapidly develop more potent inhibitors through merging of covalent and non-covalent fragment hits; one series of low-reactivity, tractable covalent fragments were progressed to discover improved binders. These combined hits offer unprecedented structural and reactivity information for on-going structure-based drug design against SARS-CoV-2 main protease.

Conor Wild

Structural Genomics Consortium

University of Oxford

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Conor Wild

.css-o250i3{font-size:18px;font-family:Open Sans,sans-serif;line-height:21.6px;}Structural Genomics Consortium

University of Oxford

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Structural Genomics Consortium